Ongoing Anticoagulant Use Does Not Avert Severe COVID-19

No reduction seen in risks for hospital admission, intensive care unit admission, or death due to COVID

white pills

FRIDAY, Dec. 4, 2020 (HealthDay News) -- Direct oral anticoagulant (DOAC) use is not associated with a reduction in the risk for severe COVID-19, according to a study published online Dec. 1 in the Journal of Internal Medicine.

Benjamin Flam, M.D., from the Karolinska University Hospital in Stockholm, and colleagues examined whether ongoing DOAC use was associated with a reduced risk for hospital admission for laboratory-confirmed COVID-19 in a nationwide register-based cohort study in Sweden in February through May 2020.

The researchers observed no association for DOAC use with a reduced risk for hospital admission for COVID-19 compared with nonuse in a comparator group of patients with atrial fibrillation (adjusted hazard ratio, 1.00; 95 percent confidence interval, 0.75 to 1.33) and in a comparator group of patients with cardiovascular disease (adjusted hazard ratio, 0.94; 95 percent confidence interval, 0.80 to 1.10). In addition, no association was seen for DOAC use with intensive care unit admission or death due to COVID-19 (adjusted hazard ratios, 0.76 [95 percent confidence interval, 0.51 to 1.12] and 0.90 [95 percent confidence interval, 0.71 to 1.15], respectively).

"Our findings suggest that early DOAC treatment doesn't protect against severe COVID-19, but these should be treated with caution since there might remain differences between the groups that are difficult to measure," Flam said in a statement. "Also, our study says nothing about whether other types of anticoagulants could be effective, but a good many clinical studies are being done around the world."

The study was funded by Janssen Corporation.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on December 04, 2020

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ